NDAINTRAVENOUSSOLUTION
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
6/8 — Strong
FOCINVEZ (fosaprepitant dimeglumine) by Aspiro Therapeutics is accordingly, its antiemetic effects are attributable to aprepitant. Approved for chemotherapy-induced nausea and vomiting. First approved in 2023.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FOCINVEZ is an intravenous fosaprepitant dimeglumine solution approved in August 2023 for chemotherapy-induced nausea and vomiting (CINV). It works as a selective neurokinin-1 (NK1) receptor antagonist that crosses the blood-brain barrier to block substance P signaling, complementing existing serotonin and corticosteroid-based therapies. The drug demonstrates efficacy against both acute and delayed phases of cisplatin-induced emesis.
Growth12.7 years to LOE
Early commercial stage with 12.7 years of patent protection creates opportunity for building market share and establishing clinical adoption programs before competitive pressure materializes.
Mechanism of Action
accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing…
Indications (1)
Worked on FOCINVEZ at Aspiro Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.